Pharmaceutical Corruption News Stories

Excerpts of Key Pharmaceutical Corruption News Stories in Major Media

Below are key excerpts of revealing news articles on pharmaceutical industry corruption from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

For further exploration, delve into our comprehensive Health and Food Corruption Information Center.

Note: This comprehensive list of news stories is usually updated once a week. Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.

In 2018, still in the throes of painful withdrawal from a psychiatric drug cocktail, U.S. Air Force veteran Derek Blumke began connecting the dots. He heard horror story after horror story that followed a disturbingly familiar pattern: starting, adjusting the dose, or abruptly stopping antidepressants was followed by personality changes, outbursts and acts of violence or suicide, leaving countless families and lives destroyed. Timothy Jensen ... an Iraq war veteran who served in the Marines, had been researching psychiatric drug overprescribing in the Veterans' Health Administration (VA) system for years. He had his own harrowing personal story of antidepressant harm, and he had lost his best friend, a fellow veteran, to suicide soon after he was prescribed Wellbutrin for smoking cessation. Poring through the data, Blumke landed on some startling statistics: 68% of all veterans seen at least one time for care at the VA in 2019 had been prescribed psychotropic drugs, and 28% were issued prescriptions for antidepressants. "It should be zero shock that veterans have the suicide rates we do," Blumke said. "Veteran suicide rates are two to two and a half times that of the civilian population. Prescription rates of antidepressants and psychiatric drugs are of the same multiples, which are both the highest in the world." Antidepressants and other psychotropic drugs have huge risk profiles, but doctors and counselors aren't even being trained about these issues.

Note: Suicide among post-9/11 veterans rose more than tenfold from 2006 to 2020. Why is Mad in America the only media outlet covering this important issue affecting so many veterans? Along these lines, the UK's medicines regulator is launching a review of over 30 commonly prescribed antidepressants, including Prozac, amid rising concerns about links to suicide, self-harm, and long-term side effects like persistent sexual dysfunction–especially in children.

Outro Health [is] a telehealth startup that CEO and cofounder Brandon Goode describes as "Uber for getting off antidepressants." Outro officially launched in the US last month and is currently available in seven states. The startup is betting that many of the growing number of Americans taking antidepressants will eventually want help coming off them. Over 11 percent of US adults took medication for depression in 2023. Research has found the prevalence of adverse withdrawal symptoms may be much higher, particularly among patients who have been on them for long periods. Outro pairs patients with a clinician who meets with them on a custom schedule and guides them through a tailored tapering program. Outro currently employs a small group of medical contractors, including nurse practitioners specializing in psychiatry and general nurse practitioners, who are supervised by psychiatrists. [British academic psychiatrist and co-founder of Outro] Mark Horowitz ... was driven by his own harrowing experience coming off antidepressants ... when he was a psychiatry doctoral student. Severe insomnia and dizziness were so debilitating ...It took me years to come off, not weeks as guidelines recommended." After he recovered, Horowitz began pushing for doctors to adopt new clinical guidelines for getting off antidepressants. He coauthored the Royal College of Psychiatry's guidance for psychiatric drug cessation and joined the UK's National Health Service as a clinical research fellow. "To me, it is actually a very leftist issue to de-medicalize the way we treat anxiety and depression," [Horowitz] says, noting that such illnesses are often caused "by social circumstances, by poverty, by loneliness."

Note: For more along these lines, read our concise summaries of news articles on Big Pharma corruption and mental health.

The Trump administration is discussing policies that would make it harder and more expensive for pharmaceutical companies to advertise directly to patients, in a move that could disrupt more than $10 billion in annual ad spending. Although the US is the only place, besides New Zealand, where pharma companies can directly advertise, banning pharma ads outright could make the administration vulnerable to lawsuits, so it's instead focusing on cutting down on the practice by adding legal and financial hurdles. The two policies the administration has focused in on would be to require greater disclosures of side effects of a drug within each ad – likely making broadcast ads much longer and prohibitively expensive – or removing the industry's ability to deduct direct-to-consumer advertising as a business expense for tax purposes. The new policies could threaten a key source of revenue to advertising and media companies, as well as the US pharmaceutical industry. Companies spent $10.8 billion in 2024 on direct-to-consumer pharmaceutical advertising in total. Before the loosening of advertising regulations by the Food and Drug Administration in 1997, US pharma companies had to list all possible side effects for a medication if they wanted to mention which condition the drug being advertised was intended to treat. Reading out a list of side effects took so long it drove up the cost for air time and meant there wasn't as much broadcast advertising as there is today.

Note: For more along these lines, read our concise summaries of news articles on Big Pharma corruption.

In 2022, three U.S. inspectors showed up unannounced at a massive pharmaceutical plant. For two weeks, they scrutinized humming production lines and laboratories spread across the dense industrial campus, peering over the shoulders of workers. Much of the factory was supposed to be as sterile as an operating room. But the inspectors discovered what appeared to be metal shavings on drugmaking equipment, and records that showed vials of medication that were "blackish" from contamination had been sent to the United States. Quality testing in some cases had been put off for more than six months, according to their report, and raw materials tainted with unknown "extraneous matter" were used anyway, mixed into batches of drugs. Sun Pharma's transgressions were so egregious that the Food and Drug Administration [banned] the factory from exporting drugs to the United States. But ... a secretive group inside the FDA gave the global manufacturer a special pass to continue shipping more than a dozen drugs to the United States even though they were made at the same substandard factory that the agency had officially sanctioned. Pills and injectable medications that otherwise would have been banned went to unsuspecting patients. The same small cadre at the FDA granted similar exemptions to more than 20 other factories that had violated critical standards in drugmaking, nearly all in India.

Note: For more along these lines, read our concise summaries of news articles on Big Pharma corruption.

As a sales rep for drug manufacturers Questcor, Lisa Pratta always suspected the company's business practices weren't just immoral but illegal, too, as she explains in "False Claims – One Insider's Impossible Battle Against Big Pharma Corruption." Pratta began working for Questcor in 2010 as the sales rep in the Northeast region for Acthar, a drug which helped relieve autoimmune and inflammatory disorders. "If prescribed correctly, Acthar could help people walk again. And talk again," writes Pratta. But, she adds, "Questcor made more money when it was prescribed incorrectly." They would do anything to sell Acthar. From paying doctors to prescribe it to using bogus research studies proclaiming its miraculous efficacy, they were so successful that Achtar's price rose from $40 per vial in 2000 to nearly $39,000 in 2019 – an increase of 97,000%. Some sales reps were making up to $4 million a year and, in turn, kept the physicians doing their bidding in a life of luxury. "They took them on scuba diving trips and bought clothes and shoes for their wives. One guy bought his doctor a brand new Armani suit and expensed it to Questcor," she recalls. In March 2019, the Department of Justice served a 100-page lawsuit against Mallinckrodt, alleging illegal marketing of Acthar, bribing doctors to boost sales and defrauding government health care programs. It also mentioned Pratta's role in the case, meaning her long-held anonymity was now public knowledge.

Note: For more along these lines, read our concise summaries of news articles on corruption in science and Big Pharma profiteering.

Too many people are being prescribed antidepressants to deal with stressful life events or social problems, according to a growing chorus of doctors and researchers. More than 14% of Australians are currently taking antidepressants, one of the highest rates in the world. Dr Matt Fisher, who researches wellbeing and the impact of stress, says while he has heard health workers talk about this "as a good thing, because it means more people are getting access to help", he doesn't see it as a success story. Fisher ... is concerned Australia's high use of antidepressants "constitutes a failed attempt to medicate away what are, in fact, social problems". He says while "antidepressants may be of benefit to some people suffering persistent psychosocial distress," they should not be the default, first response. Chronic stress, where people are exposed to an ongoing, recurrent stressor without any easy or accessible way to resolve it – increasing the risk of isolation, exclusion, humiliation and harm – is a significant driver of mental distress in Australia. The common causes of chronic stress include things such as being in debt, having a low income, poor working conditions, or being exposed to racism or domestic violence. "Governments evade the problem by persisting with individualised, medicalised, drug-based strategies," he says. "These strategies aren't reducing high rates of mental distress, sometimes do harm, and marginalise attention on social causes."

Note: The UK's medicines regulator is launching a review of over 30 commonly prescribed antidepressants, including Prozac, amid rising concerns about links to suicide, self-harm, and long-term side effects like persistent sexual dysfunction–especially in children. Our latest Substack, Lonely World, Failing Systems: Inspiring Stories Reveal What Sustains Us, dives into the loneliness crisis exacerbated by the digital world and polarizing media narratives, along with inspiring solutions and remedies that remind us of the true democratic values that bring us all together.

Joan Doyle trusts her doctors. Between her husband's epilepsy and diabetes, her daughter's Down syndrome and her own car accident years ago, the 65-year-old Sharonville resident and her family have relied on a whole host of doctors to guide them through new diagnoses and prescriptions. So when she searched her family's doctors in Open Payments, a public database that shows which doctors have received money from Big Pharma, Doyle was curious about what she'd find. "Certainly none of my doctors are on this list," she remembered thinking before searching the database. She was surprised. "Every single one of them," Doyle said. "Everybody from our dentist to our family doctor to all of our ologists." All 12 of the doctors Doyle searched accepted payments or in-kind forms of compensation from pharma or medical device companies between 2017 and 2023. The total sum varied widely, from less than $300 for her OB-GYN to more than $150,000 for her husband's oncologist. Payments like these are pervasive: A 2024 analysis found that more than half of doctors in the U.S. accepted a payment from a pharmaceutical or medical device company over the past decade. Most don't earn millions of dollars ... but research shows that when a doctor was bought a single meal of less than $20 by a drug company, they were up to twice as likely to prescribe the medication the company was marketing.

Note: 60% of U.S. doctors who shaped the DSM-5-TR–the "bible" of psychiatric diagnosis–received $14.2 million from the drug industry, raising concerns over conflicts of interest in psychiatric guidelines. For more along these lines, read our concise summaries of news articles on health and Big Pharma profiteering.

Since 1999, more than 800,000 Americans have died from opioid overdoses. The latest headlines focus on fentanyl, yet the staggering toll can be traced to the widespread availability of opioid pills made possible by decades of overprescribing. Few users start with fentanyl. Experts date the start of the opioid epidemic to within three years of the approval of OxyContin in 1995. Reports from emergency departments across the US showed Purdue's pills were being crushed and injected or snorted as early as 1997. "My eyes popped open," recalls one FDA medical officer of seeing the reports. "Nobody wanted to see it for what it was. You would've had to have your head in the sand not to know that there was something wrong." By 2000, Purdue was selling $1.1 billion annually in OxyContin. Higher doses led to higher profit. Sales reps were coached accordingly. In five years, oxycodone prescribing had surged 402%, and hospital emergency room mentions of oxycodone were up 346%. By 2012, OxyContin sales were almost $3 billion annually. And many other companies were cashing in. In the preceding six years, 76 billion opioid pills had been produced and shipped across the US, as the FDA faced a national crisis of epic proportions. In the 2010s, the US, with less than 5% of the global population, was consuming 80% of the world's oxycodone. And with coordinated pharmaceutical campaigns to destigmatize opioids, brands other than Purdue's and Roxane's benefited.

Note: Read our Substack on the dark truth of the war on drugs. Read how Congress fueled this epidemic over DEA objections. For more along these lines, read our concise summaries of news articles on government corruption and Big Pharma profiteering.

Tasha Hedges took Xanax for 20 years to treat her anxiety and panic attacks, exactly as a psychiatrist had prescribed it. Then in 2022, that doctor unexpectedly died. Discontinuing the drug typically requires decreasing the dose slowly over months or even years, a process called tapering. Ms. Hedges stopped cold turkey. Debilitating withdrawal symptoms followed: hot flashes, cold sweats, restless legs, the shakes and teeth grinding. "It was a nightmare," she said. Two years after discontinuing the medication, she is still dealing with the fallout. "My brain has not been the same." In 2019, an estimated 92 million benzodiazepine prescriptions were dispensed in the United States. Sometimes patients stay on them for years without regular check-ins to see if the drugs are still needed or well tolerated, said Dr. Edward K. Silberman ... who has frequently written about benzodiazepines. Going off the drugs – even after a short period – requires a gradual process. However, many practitioners are not well trained in tapering the prescriptions. In 2023, advocates for those injured by benzodiazepines gave a name to the varied long-lasting symptoms that may emerge during the use, the tapering or the discontinuation of the drugs: benzodiazepine-induced neurological dysfunction, or BIND. Not everyone will experience BIND, they acknowledge. And with the right tapering plan, experts say, side effects can be minimized.

Note: For more along these lines, read our concise summaries of news articles on Big Pharma corruption and mental health.

US taxpayers spent an estimated $6 billion researching, developing, and implementing new blockbuster weight-loss drugs. Yet Americans are now paying pharmaceutical giants – including one in Denmark – up to eleven times more for these medicines than patients in other countries, markups that are inflating consumers' insurance premiums and risk bankrupting the country's health care system. According to data shared with the Lever by researchers at Bentley University, the federal government spent $6.2 billion from 1980 to 2024 on the discovery and development of glucagon-like peptide-1 (GLP-1) molecules, as well as research on how to use GLP-1 drugs to treat diabetes, obesity, and other diseases. GLP-1, a hormone that regulates blood sugar, was the foundation of the diabetes drug Ozempic, whose 2017 approval by the Food and Drug Administration (FDA) launched a wave of other GLP-1-based diabetes and weight-loss medications coming to market. More than fifteen million people nationwide currently take GLP-1-related drugs like Ozempic, bringing in more than $50 billion in sales for pharmaceutical companies in 2024 – much of which went to the Danish pharmaceutical company Novo Nordisk. A Senate report ... found that if half of all Medicare and Medicaid patients with obesity took Wegovy and other GLP-1 weight-loss drugs, it could cost the federal health care system $166 billion per year.

Note: The makers of these weight-loss drugs could be hit with over 10,000 lawsuits over severe adverse events from these drugs. For more along these lines, read our concise summaries of news articles on corruption in government and in Big Pharma.

Patients prescribed drugs for movement disorders - including restless leg syndrome (RLS) - say doctors did not warn them about serious side effects that led them to seek out risky sexual behaviour. Twenty women have told the BBC that the drugs - given to them for RLS, which causes an irresistible urge to move - ruined their lives. A report by drugs firm GSK - seen by the BBC - shows it learned in 2003 of a link between the medicines, known as dopamine agonist drugs, and what it described as "deviant" sexual behaviour. It cited a case of a man who had sexually assaulted a child while taking the drug for Parkinson's. Some of the women who described being drawn to risky sexual behaviour told us they had no idea of what was causing it. Others said they felt compelled to gamble or shop with no history of such activities. Impulsive behaviours, including gambling and increased sex drive, have long been listed as side effects in medicine leaflets for dopamine agonist drugs - and are thought to affect between 6% to 17% of RLS patients taking them, according to health guidance body NICE. The cases of what the GSK report from 2003 described as "deviant behaviour" involved two men who were prescribed Ropinirole for Parkinson's disease. In one, a 63-year-old-man sexually assaulted a seven-year-old girl, leading to a custodial sentence. In the second case, a 45-year-old man carried out "uncontrolled acts of exhibitionism and indecent behaviour".

Note: For more along these lines, read our concise summaries of news articles on Big Pharma corruption.

The former head of the Food and Drug Administration's (FDA) drug division is joining Pfizer as its chief medical officer. Patrizia Cavazzoni was formerly director of the FDA's Center for Drug Evaluation and Research (CDER) from 2020 until January, when she resigned just ahead of President Trump's return to office. Cavazzoni previously worked at Pfizer prior to joining the FDA in 2018. The announcement spurred renewed criticisms about the common "revolving door" between the FDA and industry. Critics worry the close relationship leads to a quid pro quo and favoritism toward industry. Scott Gottlieb, FDA commissioner during Trump's first term, now serves on the board of Pfizer. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has long accused the FDA of being corrupt and beholden to industry influence and has pledged to root out supposed conflicts of interest across the agency. Just ahead of the election, while Trump was considering him for HHS secretary, Kennedy posted on social media that FDA employees who are "part of this corrupt system" should "pack their bags." Watchdog group Public Citizen panned Cavazzoni's hiring. "Cavazonni's move demonstrates that the revolving door between the FDA and the industries it regulates is alive and well and continues to undermine the FDA's credibility as a public health agency," the organization's health research group director Robert Steinbrook said.

Note: For more along these lines, read our concise summaries of news articles on corruption in government and in Big Pharma.

Nick was 19 when a psychiatrist offered him the antidepressant Trintellix to treat his moderate anxiety and depression after just a few short visits. Going on the popular selective serotonin reuptake inhibitor (SSRI) ... didn't seem like a big deal at the time. But, when Nick went off the medication after six years, he immediately noticed his genitals were losing sensation. Over the course of a couple weeks, he almost entirely lost feeling in the area – and it never returned, nor did the high sex drive he once had. He would ultimately learn he suffers from Post-SSRI Sexual Dysfunction (PSSD). "I wasn't at risk of taking my own life or anything like that … I still had a hell of a lot of fun in life … I think I definitely should have [done] therapy first and foremost," he said. "Now there's just no enjoyment in anything. It's like watching a brick wall." For many, antidepressants are lifesaving treatments, but, in rare instances, they can potentially cause debilitating side effects that persist for years after stopping the drugs. SNOMED, the National Institute Of Health's official source of medical terminology for US healthcare systems, recognizes PSSD as a legitimate disorder as of last year, defining it as "persistent sexual side effects" including genital numbness and loss of libido that "can last for weeks, months, or even years after stopping" antidepressants. The rate of prescriptions for those ages 12 to 25 jumped by about two-thirds from 2016 to 2022. "The studies that were done for SSRIs to be approved by the FDA were not done on children, they were done on adults," [clinical psychologist Meg Jay] said. "But now it's much more common for tweens and teens to be prescribed medications than it used to be." In the past two years alone, [Psychopharmacologist and former professor of psychiatry David Healy] said he's known more than a dozen people, many of them young, who were so distressed by PSSD that they committed suicide.

Note: For more along these lines, read our concise summaries of news articles on Big Pharma corruption.

Antidepressants are frequently prescribed to people with dementia for symptoms like anxiety, depression, aggressiveness and sleeplessness. But a specific class of antidepressant medications - selective serotonin reuptake inhibitors (SSRIs) - actually might speed up brain decline among some dementia patients, a new Swedish study suggests. Heavier doses of certain SSRIs are tied to a higher risk for severe dementia, researchers reported in a new study ... in the journal BMC Medicine. The SSRI drug escitalopram was associated with the fastest cognitive decline, followed by citalopram and sertraline. For the study, researchers tracked the brain health of more than 18,700 patients enlisted in the Swedish Registry for Cognitive/Dementia Disorders between May 2007 and Oct. 2018. The patients' average age was 78. During an average follow-up of more than four years, about 23% of patients received a new prescription for an antidepressant, researchers said. SSRIs were the most commonly prescribed antidepressant, amounting to 65% of all those prescriptions, the study says. "Higher dispensed doses of SSRIs were associated with higher risk for severe dementia, fractures, and all-cause mortality," the researchers concluded. "These findings highlight the significance of careful and regular monitoring to assess the risks and benefits of different antidepressants use in patients with dementia."

Note: For more along these lines, read our concise summaries of news articles on Big Pharma corruption.

More than 30 of the most common antidepressants used in the UK are to be reviewed by the UK's medicines regulator, as figures point to hundreds of deaths linked to suicide and self-harm among people prescribed these drugs. The medicines, which include Prozac and are prescribed to millions of patients, will all be looked at by the Medicines and Healthcare products Regulatory Agency (MHRA). It follows concerns raised by families in Britain over the adequacy of safety measures in place to protect those taking the drugs, such as warnings about potential side effects. There has been a huge rise in the use of antidepressants in England, with 85 million prescriptions issued in 2022-23, up from 58 million in 2015-16, according to NHS figures. Nigel Crisp, a crossbench peer and chair of the Beyond Pills all-party parliamentary group, [said]: "Overprescribing of antidepressants has an enormous cost in terms of human suffering, because so many people become dependent and then struggle to get off them – and it wastes vital NHS resources." More than 515 death alerts linked to these drugs, involving suicidal ideation and self-harm, have been made to the MHRA since the year 2000. Some antidepressants have been given to children as young as four, and the total cost of the medication to the NHS in 2022-23 was more than Ł231m. Side effects of many antidepressants can include suicidal thoughts and anxiety, according to the National Institute for Health and Care Excellence.

Note: A UK coroner has issued a warning about the effects of antidepressants and how their use could lead to more deaths without a change in guidance and labeling about the risks. For more along these lines, read our concise summaries of news articles on mental health and Big Pharma corruption.

In 2017, the drug industry middleman Express Scripts announced that it was taking decisive steps to curb abuse of the prescription painkillers that had fueled America's overdose crisis. Why hadn't the middlemen, known as pharmacy benefit managers, acted sooner to address a crisis that had been building for decades? One reason, a New York Times investigation found: Drugmakers had been paying them not to. For years, the benefit managers, or P.B.M.s, took payments from opioid manufacturers, including Purdue Pharma, in return for not restricting the flow of pills. As tens of thousands of Americans overdosed and died from prescription painkillers, the middlemen collected billions of dollars in payments. The P.B.M.s exert extraordinary control over what drugs people can receive and at what price. The three dominant companies – Express Scripts, CVS Caremark and Optum Rx – oversee prescriptions for more than 200 million. The P.B.M.s are hired by insurers and employers to control their drug costs by negotiating discounts with pharmaceutical manufacturers. They often pursue their own financial interests in ways that increase costs for patients, employers and government programs, while driving independent pharmacies out of business. Regulators have accused the largest P.B.M.s of anticompetitive practices. In addition ... P.B.M.s sometimes collaborated with opioid manufacturers to persuade insurers not to restrict access to their drugs.

Note: A former DEA agent has said that Congress helped drug companies create the opioid epidemic. Read how pharmacy benefit managers inflate the price of medications behind the scenes. For more along these lines, read our concise summaries of news articles on Big Pharma corruption.

New rules require drugmakers to be clearer and more direct when explaining their medications' risks and side effects. The [new] guidelines ... are designed to do away with industry practices that downplay or distract viewers from risk information. But while regulators were drafting them, a new trend emerged: Thousands of pharma influencers pushing drugs online with little oversight. A new bill in Congress would compel the FDA to more aggressively police such promotions on social media platforms. "Some people become very attached to social media influencers and ascribe to them credibility that, in some cases, they don't deserve," said Tony Cox ... at Indiana University. Still, TV remains the industry's primary advertising format, with over $4 billion spent in the past year. Even so, many companies are looking beyond TV and expanding into social media. They often partner with patient influencers who post about managing their conditions, new treatments or navigating the health system. Advertising executives say companies like the format because it's cheaper than TV and consumers generally feel influencers are more trustworthy than companies. "The power of social media and the deluge of misleading promotions has meant too many young people are receiving medical advice from influencers instead of their health care professional," Sens. Dick Durbin of Illinois and Mike Braun of Indiana wrote the FDA in a February letter.

Note: Prescription drug advertising is only legal in the US and New Zealand. Read more about the influencers who are paid to promote pharmaceuticals on social media. For more along these lines, read our concise summaries of news articles on Big Pharma profiteering and media manipulation.

U.S. government researchers have found that a widely prescribed asthma drug originally sold by Merck & Co, may be linked to serious mental health problems for some patients, according to a scientific presentation reviewed by Reuters. The researchers found that the drug, sold under the brand name Singulair and generically as montelukast, attaches to multiple brain receptors critical to psychiatric functioning. By 2019, thousands of reports of neuropsychiatric episodes, including dozens of suicides, in patients prescribed the drug had piled up on internet forums and in the U.S. Food and Drug Administration's tracking system. Such "adverse event" reports do not prove a causal link between a medicine and a side effect, but are used by the FDA to determine whether more study of a drug's risks are warranted. The reports and new scientific research led the FDA in 2020 to add a "black box" warning to the montelukast prescribing label, flagging serious mental health risks like suicidal thinking or actions. The behavior of montelukast appears similar to other drugs known to have neuropsychiatric effects, such as the antipsychotic risperidone. When the FDA added the black box, it cited research from Julia Marschallinger and Ludwig Aigner. The two scientists told Reuters ... the new data showed significant quantities of montelukast present in the brain. The receptors involved play a role in governing mood, impulse control, cognition and sleep, among other functions, they said.

Note: Reuters reported that the FDA received more than 80 reports of suicides in people taking the medicine. Learn more about how US courts protected Merck from lawsuits regarding Singulair. For more along these lines, explore concise summaries of news articles on mental health and Big Pharma profiteering from reliable major media sources.

Pfizer Inc. failed to warn patients that its injectable contraceptive drug Depo-Provera can increase the risk of developing brain tumors, a new lawsuit alleged. "For several decades the manufacturers and sellers of Depo-Provera and its authorized generic and generic analogues" had a responsibility to investigate whether the medication could contribute to the growth of brain tumors, according to the complaint filed Monday in the US District Court for the Central District of California. Plaintiff Taylor Devorak alleged that researchers have found Depo-Provera and similar progesterone medications have been linked to a greater incidence of brain tumors called intracranial meningioma. She's seeking damages on her failure-to-warn, defective design, negligence, misrepresentation, and breach of warranty claims against the pharmaceutical giant. Devorak's complaint comes in the wake of a handful of substantially similar lawsuits filed in other federal courts in California and Indiana in recent weeks. The American label for Depo-Provera "still makes no mention of the increased risk to patients of developing intracranial meningiomas," even though the EU and UK now list meningioma under the medication's warning section, Devorak's complaint said. Devorak cited a 2024 study published in the British Medical Journal that said prolonged use of medroxyprogesterone acetate medications like Depo-Provera were found to significantly increase the risk of developing intracranial meningioma.

Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

AstraZeneca is being sued by a woman who claims she was disabled by the company's Covid-19 vaccine. Brianne Dressen said she was "the picture of good health" when getting the AstraZeneca Covid vaccine in 2020 at the age of 39 through a Salt Lake County, Utah, clinical trial. In the hours that followed, her arm began to tingle and the feeling spread up to her shoulder, then to her opposite arm. Later, other symptoms followed, including blurred vision, a headache, ringing ears, and vomiting. In 2021, National Institutes of Health neurologists diagnosed her with "post vaccine neuropathy." Dressen is the co-chair of React19, an interest group for people alleging injury from Covid-19 vaccines. Now, she's suing AstraZeneca over medical expenses and more, arguing she's still disabled and unable to work and carry on with many activities as she once had. The lawsuit, which accuses AstraZeneca of breaching contractual obligations, comes days after AstraZeneca pulled its Covid-19 vaccine off the market. AstraZeneca has said it was doing so due to a lack of demand and not for safety reasons. The vaccine, however, has faced concerns over its efficacy and safety. As of April 1, over 10,000 claims alleging injury or death from a Covid-19 shot have been filed with the Countermeasures Injury Compensation Program, according to the HHS. In a separate lawsuit, Dressen's React19 and people alleging vaccine injuries are suing the HHS over the program.

Note: People injured by AstraZeneca's vaccine were censored on social media when they tried to talk about their experiences. While mainstream narratives emphasize how rare these injuries are, the numbers speak for themselves. The Vaccine Adverse Event Reporting System (VAERS) is a voluntary government reporting system that only captures a portion of the actual injuries. Vaccine adverse event numbers are made publicly available, and currently show 38,068 COVID Vaccine Reported Deaths and 1,652,230 COVID Vaccine Adverse Event Reports.

Important Note: Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.